JAMA Oncology
Brief Report
April 25, 2024
Giacomo听Montagna,听MD, MPH; Mary M.听Mrdutt,听MD, MS; Susie X.听Sun,听MD; Callie听Hlavin,听MD, MPH; Emilia J.听Diego,听MD; Stephanie M.听Wong,听MD, MPH; Andrea V.听Barrio,听MD; Astrid Botty听van den Bruele,听MD; Neslihan听Cabioglu,听MD, PhD; Varadan听Sevilimedu,听MBBS, DrPH; Laura H.听Rosenberger,听MD, MS; E. Shelley听Hwang,听MD, MPH; Abigail听Ingham,听MBchB; B盲rbel听Papassotiropoulos,听MD; Bich Doan听Nguyen-Str盲uli,听MD; Christian听Kurzeder,听MD; Danilo D铆az听Aybar,听MD; Denise听Vorburger,听MD; Dieter Michael听Matlac,听MD; Edvin听Ostapenko,听MD; Fabian听Riedel,听MD; Florian听Fitzal,听MD; Francesco听Meani,听MD; Franziska听Fick,听MD; Jacqueline听Sagasser,听MD; J枚rg听Heil,听MD, PhD; Hasan听Karanl谋k,听MD; Konstantin J.听Dedes,听MD; Laszlo听Romics,听MD, PhD; Maggie听Banys-Paluchowski,听MD, PhD; Mahmut听Muslumanoglu,听MD; Maria Del Rosario Cueva听Perez,听MD; Marcelo Ch谩vez听D铆az,听MD; Martin听Heidinger,听MD; Mathias K.听Fehr,听MD; Mattea听Reinisch,听MD; Mustafa听Tukenmez,听MD; Nadia听Maggi,听MD; Nicola听Rocco,听MD, PhD; Nina听Ditsch,听MD, PhD; Oreste Davide听Gentilini,听MD; Regis R.听Paulinelli,听MD, PhD; Sebasti谩n Sol茅听Zarhi,听MD; Sherko听Kuemmel,听MD, PhD; Simona听Bruzas,听MD; Simona听di Lascio,听MD; Tamara K.听Parissenti,听MD; Tanya L.听Hoskin,听MS; Uwe听G眉th,听MD; Valentina听Ovalle,听MD; Christoph听Tausch,听MD; Henry M.听Kuerer,听MD, PhD; Abigail S.听Caudle,听MD; Jean-Francois听Boileau,听MD, MSc; Judy C.听Boughey,听MD; Thorsten听K眉hn,听MD, PhD; Monica听Morrow,听MD; Walter P.听Weber,听MD
online first
JAMA Oncol. 2024; 10.1001/jamaoncol.2024.0578
This cohort study examines oncological outcomes after sentinel lymph node biopsy with dual-tracer mapping or targeted axillary dissection.
JAMA Oncology
Original Investigation
June 1, 2016
Kristine R.听Broglio,听MS; Melanie听Quintana,听PhD; Margaret听Foster,听MS; Melissa听Olinger,听BA; Anna听McGlothlin,听PhD; Scott M.听Berry,听PhD; Jean-贵谤补苍莽辞颈蝉听Boileau,听MD; Christine听Brezden-Masley,听MD; Stephen听Chia,听MD; Susan听Dent,听MD; Karen听Gelmon,听MD; Alexander听Paterson,听MD; Daniel听Rayson,听MD; Donald A.听Berry,听PhD
free access
JAMA Oncol. 2016; 2(6):751-760. 10.1001/jamaoncol.2015.6113
This meta-analysis of 36 randomized clinical trials and cohort studies of 5768 patients with HER2-positive breast cancer investigates the association between pathologic complete response to therapy and time to recurrence and death.